JOGO Health, a prescription digital therapeutics company headquartered in New Jersey, USA has announced a collaboration with Mayo Clinic aimed at advancing the understanding and treatment of various tremors like Parkinson’s tremors, functional tremors (FT) & essential tremors (ET). Under the new partnership, combining medical analysis and device development expertise, the two entities seek to pioneer AI-driven digital therapeutics for these conditions.

The joint study will focus on developing specialized treatments particularly for functional tremors, which currently lack effective medical therapy options and often require patients to take extended time off work or school. Mayo Clinic has a financial stake in the technology mentioned here, using revenue generated to advance its nonprofit commitment to patient care, education, and research. The collaborative study, set to commence in September 2024. JOGO, has already demonstrated early success in treating Parkinson’s disease.

JOGO incorporated a patented AI-driven wearable sensor applying the science of EMG Biofeedback facilitating neuroplasticity. JOGO is a non-invasive, portable, wireless digital device that is 510K exempted by the US FDA.

JOGO Health has operations in India at 10 major cities including Delhi, Mumbai, Bangalore, Chennai & Kolkata. JOGO Health intends to expand its services to 20 cities by 2025.